Date: 2015-02-27
Type of information: Nomination
Compound:
Company: Macrophage Therapeutics (USA - OH)
Therapeutic area: Cancer - Oncology - Immunological diseases - Autoimmune diseases - Cardiovascular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 27, 2015, Macrophage Therapeutics, a subsidiary of Navidea Biopharmaceuticals, announced the appointment of leading experts to a newly formed scientific advisory board (SAB) to serve as a strategic resource to Macrophage Therapeutics as it looks to develop therapeutic applications for Navidea’s innovative Manocept™ platform. The inaugural SAB consortium is comprised of scientists and clinicians in the areas of oncology, immunology, autoimmune diseases and macrophage biology. The SAB will serve as an ongoing resource to provide management with counsel and guidance pertaining to the research, development, and clinical application of Manocept technology. The inaugural members of Macrophage Therapeutics’ Scientific Advisory Board include:Siamon Gordon, M.B., Ch.B., Ph.D. (Glaxo Wellcome Professor of Cellular Pathology (Emeritus), University of Oxford), Mark I. Greene, M.D., Ph.D., F.R.C.P., John Eckman Professor of Medical Sciences, (Vice Chair of Pathology, Division of Immunology and Experimental Pathology, University of Pennsylvania), Wael Jarjour, M.D. (Associate Professor, Director, Division of Rheumatology & Immunology, The Ohio State University), Michael S. McGrath, M.D., Ph.D. Professor, (Departments of Laboratory Medicine, Pathology, and Medicine, University of California San Francisco), Thomas J. Rosol, D.V.M., Ph.D. (Professor, Veterinary Sciences, The Ohio State University; Senior Advisor, Life Sciences, University Office of Technology Commercialization and Knowledge Transfer, The Ohio State University; Special Assistant to the Vice President for Research, The Ohio State University), Eric K. Rowinsky, M.D. (Head of Research and Development and Chief Medical Officer,Stemline Therapeutics, Inc. and Director of Navidea Biopharmaceuticals), Larry S. Schlesinger, M.D. (Chair, Department of Microbial Infection and Immunity, Director, Center for Microbial Interface Biology, The Ohio State University), David Sidransky, M.D. (Professor of Otolaryngology – Head and Neck Surgery, Professor of Oncology, Professor of Pathology, Professor of Cellular & Molecular Medicine, Professor of Urology, and Director, Head and Neck Cancer Research, The Johns Hopkins University), Kenneth C. Williams, Ph.D. (Professor of Biology, Boston College) Macrophage Therapeutics is developing innovative macrophage-targeted therapies for oncology, inflammatory, autoimmune and cardiovascular applications based on Navidea’s proprietary CD206 targeting technology platform, Manocept™. Depending on the active agent(s) attached to the Manocept backbone as well as other core molecule permutations, it is possible to approach immunotherapy in a completely novel manner. This approach has the potential to provide for management and modification of diseases that include the immediate involvement of macrophages, the biological products of macrophages, or the effective impact of macrophages or their progenitor and/or daughter elements. Thus, the Manocept platform is designed to specifically address a key element, macrophage interactions, in the natural progression of clinically significant diseases that impact the lives of patients around the globe.
Financial terms:
Latest news:
